Anixa Biosciences Inc

ANIXReported to SECin USCIK 0000715446Filings at SEC EDGAR

No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 18. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

The most recent filings

Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.

5 of 18
Form 4 lines at Anixa Biosciences Inc, most recent filing first
Filed byTypeValueReportedFiled byValueTypeSharesReported
Catelani MichaelPresident, COO, & CFOOpen-market buy$15,6205,500 sharesSep 30, 2026Catelani MichaelPresident, COO, & CFO$15,620Buy · Sep 30Open-market buy5,500Sep 30, 2026
KUMAR AMITChief Executive OfficerOpen-market buy$19,4607,000 sharesSep 28, 2026KUMAR AMITChief Executive Officer$19,460Buy · Sep 28Open-market buy7,000Sep 28, 2026
Baskies Arnold M—Open-market buy$13,8005,000 sharesSep 28, 2026Baskies Arnold M$13,800Buy · Sep 28Open-market buy5,000Sep 28, 2026
Titterton Lewis H jr—Open-market buy$131,90749,036 sharesSep 25, 2026Titterton Lewis H jr$131,907Buy · Sep 25Open-market buy49,036Sep 25, 2026
KUMAR AMITChief Executive OfficerOpen-market buy$8,2503,000 sharesSep 14, 2026KUMAR AMITChief Executive Officer$8,250Buy · Sep 14Open-market buy3,000Sep 14, 2026